Fish oil, krill oil, or algal oil: which is best for omega-3?

How it works

Krill phospholipid-bound omega-3 is sometimes claimed to be better absorbed than triglyceride-bound; small bioavailability studies show modest pharmacokinetic differences but clinical-outcome equivalence at lower doses is not established head-to-head. Krill also contains astaxanthin (carotenoid antioxidant) and choline (lipid-soluble methyl donor), genuine ancillary compounds with their own evidence bases for skin and liver health respectively, separate from omega-3 effects. Plant-source omega-3 (ALA, alpha-linolenic acid) requires hepatic conversion to EPA (around 5-10%) and DHA (less than 1%) and is not a reliable substitute for pre-formed EPA+DHA at therapeutic doses.

Effective dose

Krill oil per-capsule content: typically 200-300 mg EPA+DHA per 1000 mg krill oil capsule vs 500-700 mg per concentrated fish oil capsule. Reaching therapeutic doses (2-4 g EPA+DHA/day) requires considerably more capsules with krill oil. Cost per gram of EPA+DHA is meaningfully higher than fish oil. ALA conversion: 5-10% to EPA, less than 1% to DHA in most adults; lower in men, lower with high omega-6 intake, affected by FADS1/FADS2 polymorphisms. Algal oil bypasses this conversion bottleneck.

Forms compared

Fish oil quality: choose molecularly distilled formulations with IFOS or similar third-party purity and oxidation testing. Common concerns: fishy aftertaste (mitigated by enteric-coated softgels or storing in freezer), heavy metals (well-controlled in tested products), oxidation (TOTOX value matters; rancid oil is pro-inflammatory). Krill oil sustainability: improved with Marine Stewardship Council certification but remains a consideration. Algal oil: sustainable and free from any fish-derived contaminants. EPA-deficient pure-DHA algal oil is suboptimal for EPA-relevant indications (mood, CV); choose products with both EPA and DHA where indication requires EPA. See dedicated molecular form entry for TG vs EE vs FFA vs rTG within fish oil.

Timing

For oxidative integrity: storage cool and dark, ideally refrigerated after opening. Consume by expiry date. Higher therapeutic doses mean more capsules; choosing concentrated formulations reduces capsule load and storage burden. Practical retest schedule for omega-3 index: baseline before starting; 3-4 months after consistent dosing to confirm tissue incorporation.

Safety profile

Fish oil heavy metal concerns: well-controlled in tested products; dietary fish like wild salmon also has very low contaminant levels per FSA data. Rancid omega-3 has reduced biological activity and may be pro-inflammatory rather than anti-inflammatory. Krill oil pregnancy data is more limited than fish or algal oil; not specifically recommended in UK NHS pregnancy guidance. Practical signs of rancidity across all forms: strong fishy or off smell, dark or cloudy oil, fishy burp or aftertaste.

Special populations

Fish allergy: algal oil; krill oil contains crustacean protein and is contraindicated in shellfish allergy. Statin users: NICE NG238 contraindicates combining a statin with an omega-3 fatty acid compound except icosapent ethyl per specific TA; coordinate with prescribing clinician. Anticoagulated patients: see omega-3 plus warfarin entry. Older adults: AF signal at 4 g/day is more clinically relevant. EPA-deficient pure-DHA products are suboptimal for mood and cardiovascular indications where EPA is the relevant fraction.

Interactions

Vitamin K antagonists (warfarin): UK BNF flags INR monitoring when starting or stopping high-dose omega-3; see dedicated entry c7e5fa4a. Antiarrhythmic medications: AF signal at 4 g/day in REDUCE-IT and STRENGTH is relevant when initiating high-dose omega-3 in users with AF history. Krill oil and crustacean allergy: krill oil contains crustacean protein and is contraindicated in shellfish allergy.

Guideline positions

Almost the entire major clinical trial evidence base for omega-3 (REDUCE-IT, STRENGTH, VITAL) is on fish-derived omega-3 (whether as pure EPA icosapent ethyl, mixed EPA/DHA ethyl ester, or carboxylic acid). Krill and algal sources have not been the subject of equivalent large outcome trials; supportive evidence is by extrapolation from EPA+DHA equivalence and from smaller pharmacokinetic and biomarker studies. EFSA recommends pregnant and lactating women aim for an additional 100-200 mg DHA/day on top of general adult intake of around 250 mg EPA+DHA/day, given DHA structural role in foetal brain and eye development.

Practical framework

Pregnancy framework: algal oil for predictable contaminant-free DHA; concentrated fish oil supplements at recommended doses are reasonable alternatives within the NHS framework; do not exceed 3 g/day combined EPA+DHA from supplements without clinical supervision. For oxidative integrity: choose products with current third-party oxidation testing; IFOS-certified or equivalent; consume by expiry date. Read EPA + DHA content per capsule, not total oil weight, and do realistic capsule-count arithmetic before committing to a form at a given target dose. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: ALA from flaxseed, chia, or walnut is a reliable substitute for fish or algal oil at therapeutic doses. Conversion is around 5-10% to EPA and less than 1% to DHA in most adults; lower in men, lower with high omega-6 intake, affected by FADS1/FADS2 polymorphisms. Plant ALA is valuable for general dietary pattern but not a therapeutic-dose substitute for pre-formed EPA+DHA.

Claim: pure-DHA algal oil is interchangeable with EPA+DHA fish oil. EPA-deficient pure-DHA products are suboptimal for EPA-relevant indications (mood, cardiovascular).

Claim: any form is fine in pregnancy. Cod liver oil is contraindicated (vitamin A teratogenic at high intake); krill oil pregnancy data is limited; algal oil and standard fish oil within UL framework are the appropriate choices.